Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3448)
Drug Name
Tivantinib
Synonyms
Tivantinib; 905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; Tivantinib; ARQ197; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102
Indication Hepatocellular carcinoma [ICD11: 2C12] Phase 3 [1]
Solid tumour/cancer [ICD11: ICD11: 2A00-2F9Z] Phase 3 [2]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 369.4 Topological Polar Surface Area 66.9
Heavy Atom Count 28 Rotatable Bond Count 2
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 2
Cross-matching ID
PubChem CID
11494412
ChEBI ID
CHEBI:91398
CAS Number
905854-02-6
TTD Drug ID
D0ZI1F
Formula
C23H19N3O2
Canonical SMILES
C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65
InChI
InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1
InChIKey
UCEQXRCJXIVODC-PMACEKPBSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Tivantinib Metabolite M10 DM019145 N. A. Oxidation - Oxidation 1 [3]
Tivantinib Metabolite M4 DM016271
67980285
Unclear - Unclear 1 [3]
Tivantinib Metabolite M5 DM019143 N. A. Unclear - Unclear 1 [3]
Tivantinib Metabolite M8 precursor DM019139 N. A. Unclear - Unclear 1 [3]
Tivantinib Metabolite M11 DM019142 N. A. Oxidation - Oxidation 2 [3]
Tivantinib Metabolite M12 DM019144 N. A. Oxidation - Oxidation 2 [3]
Tivantinib Metabolite M15,16 DM019141 N. A. Unclear - Unclear 2 [3]
Tivantinib Metabolite M6 DM016184
57404272
Unclear - Unclear 2 [3]
Tivantinib Metabolite M8 DM016185
57405789
Unclear - Unclear 2 [3]
Tivantinib Metabolite M9 DM019140 N. A. Oxidation - Oxidation 3 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR011600 Tivantinib Tivantinib Metabolite M8 precursor Unclear - Unclear Unclear [3]
MR011603 Tivantinib Tivantinib Metabolite M4 Unclear - Unclear CYP3A4 ... [3]
MR011607 Tivantinib Tivantinib Metabolite M5 Unclear - Unclear Unclear [3]
MR011610 Tivantinib Tivantinib Metabolite M10 Oxidation - Oxidation CYP3A4 ... [3]
MR011604 Tivantinib Metabolite M4 Tivantinib Metabolite M6 Unclear - Unclear ADH4 [3]
MR011605 Tivantinib Metabolite M4 Tivantinib Metabolite M15,16 Unclear - Unclear UGT1A9 [3]
MR011606 Tivantinib Metabolite M4 Tivantinib Metabolite M11 Oxidation - Oxidation CYP3A4 ... [3]
MR011608 Tivantinib Metabolite M5 Tivantinib Metabolite M15,16 Unclear - Unclear UGT1A9 [3]
MR011609 Tivantinib Metabolite M5 Tivantinib Metabolite M12 Oxidation - Oxidation CYP3A4 ... [3]
MR011601 Tivantinib Metabolite M8 precursor Tivantinib Metabolite M8 Unclear - Unclear ADH4 [3]
MR011602 Tivantinib Metabolite M8 Tivantinib Metabolite M9 Oxidation - Oxidation CYP3A4 ... [3]
⏷ Show the Full List of 11 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Alcohol dehydrogenase class-II (ADH4) DME0130 Homo sapiens
ADH4_HUMAN
1.1.1.105
[3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[3]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[3]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DME0042 Homo sapiens
UD19_HUMAN
2.4.1.17
[3]
References
1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
3 Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.